share_log

Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13

Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13

摩根士丹利以同等權重評級啓動對ProKidney的保險,宣佈目標股價爲13美元
Benzinga Real-time News ·  2022/11/10 08:02

Morgan Stanley analyst Vikram Purohit initiates coverage on ProKidney (NASDAQ:PROK) with a Equal-Weight rating and announces Price Target of $13.

摩根士丹利分析師維克拉姆·普羅希特以同等權重評級啓動了對ProKidney(納斯達克股票代碼:PROK)的報道,並宣佈目標股價爲13美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論